Investor type Venture Capital
Founders Luc Verelst


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 17
Average round size
The average size of a deal this fund participated in
Portfolio companies 12
Rounds per year 1.70
Lead investments 2
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees 6

Areas of investment

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Health Care
  • Therapeutics

DROIA appeared to be the VC, which was created in 2011. The main office of represented VC is situated in the Luxembourg. The fund was located in Europe if to be more exact in Luxembourg.

The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Therapeutics, Business Development. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Frontier Medicines, Cyteir Therapeutics, OCTIMET Oncology.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the DROIA, startups are often financed by Celgene, The Column Group, Venrock. The meaningful sponsors for the fund in investment in the same round are Celgene, Venrock, The Column Group. In the next rounds fund is usually obtained by Celgene, Wellington Management, Venrock.

This organization was formed by Luc Verelst. Besides them, we counted 2 critical employees of this fund in our database.

The top amount of exits for fund were in 2018. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. This DROIA works on 16 percentage points less the average amount of lead investments comparing to the other organizations.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ABCI Investment Management -
Alpha Group France, Ile-de-France, Paris
b-ventures Italy, Lombardy, Milan
Belkin International California, Playa Vista, United States
BlueStream Ventures Minnesota, Stillwater, United States
En-Japan Japan, Yamanashi, Yamanashi Prefecture
French sovereign investment bank -
Geocapital Partners Fort Lee, New Jersey, United States
HamiltonApex Technology Ventures California, Solana Beach, United States
Huatailai Investment Beijing, China, Haidian
Insignia Financial Group Greenville, South Carolina, United States
ITEC HANKYU HANSHIN Japan, Osaka, Osaka Prefecture
Jefferson Capital Partners Louisiana, Mandeville, United States
Keppel Capital Central, Central Region, Singapore
Patni Family -
Penja Strategy -
Sustainable Income Capital Management -
Vayner/RSE New York, New York, United States
Vine Ventures -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Frontier Medicines

Artificial Intelligence
$88M19 Jul 2021 San Francisco, California, United States

Hummingbird Bioscience

Health Care
$125M18 May 2021 Singapore, Central Region, Singapore

$32M06 Apr 2021 New York, New York, United States

Cyteir Therapeutics

$80M11 Feb 2021 Cambridge, Massachusetts, United States

Vico Therapeutics

Health Care
$31M29 Jul 2020 Leiden, South Holland, Netherlands


Health Care
$42M13 May 2020 Cambridge, Massachusetts, United States

Accent Therapeutics

$63M23 Apr 2020 Lexington, Kentucky, United States

Volastra Therapeutics

$12M11 Feb 2020 New York, New York, United States

PACT Pharma

Health Care
Personal Health
$75M11 Jan 2020 Hayward, California, United States
Hummingbird Bioscience Raises US$125M in Series C Financing

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent DROIA?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: